Arrowhead Pharmaceuticals develops and commercializes RNA interference medicines that silence genes associated with intractable diseases. The company’s TRiM™ platform is used to design targeted RNAi therapeutics for tissues including liver, lung, muscle, adipose and central nervous system tissue.
Recurring ARWR news covers REDEMPLO® (plozasiran), an siRNA medicine approved in the United States and Australia as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. Company updates also address plozasiran data across hypertriglyceridemia, regulatory actions in additional geographies, pricing and market-access strategy, fiscal results, investor events, and clinical or partnering developments involving programs such as ARO-PNPLA3, ARO-INHBE and ARO-ALK7.
ADT (NYSE: ADT) will join the S&P SmallCap 600 effective prior to the opening of trading on Feb 9, 2026, as part of index changes by S&P Dow Jones Indices. The rebalancing also adds Ciena (CIEN) to the S&P 500 and moves Arrowhead Pharmaceuticals (ARWR) into the S&P MidCap 400 on Feb 9; OneSpaWorld (OSW) joins the SmallCap 600 on Feb 10.
Dayforce was removed following an acquisition by Thoma Bravo, and Dynavax was deleted ahead of its pending acquisition by Sanofi.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has dosed the first subjects in a Phase 1/2a study of ARO-DIMER-PA, described as the first clinical RNAi candidate designed to silence two genes with one molecule (PCSK9 and APOC3) using Arrowhead's TRiM™ platform. Preclinical data in hyperlipidemic nonhuman primates showed potent lowering of PCSK9 and APOC3 and reductions in non-HDL cholesterol, LDL-C, and triglycerides. The study advances Arrowhead's cardiometabolic RNAi portfolio alongside approved REDEMPLO and ongoing programs.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a live webcast and conference call on February 5, 2026 at 4:30 p.m. ET to discuss fiscal 2026 first quarter results for the period ended December 31, 2026. Investors can access the live audio webcast via the company's Events and Presentations page under Investors. A replay will be available approximately two hours after the call ends. Analysts wishing to join the conference call must register to receive a dial-in number and a personalized PIN to access the call.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) priced concurrent offerings: $625,000,000 aggregate 0.00% convertible senior notes due 2032 and 3,100,776 shares of common stock at $64.50 per share (or up to 1,550,387 pre-funded warrants at $64.499 each). Note settlement is scheduled for January 12, 2026; equity settlement is scheduled for January 9, 2026. Net proceeds are estimated at approximately $608.2M from notes and $188.3M from the common stock offering (pro forma higher if underwriters exercise options). Initial conversion rate is 11.4844 shares per $1,000 principal (≈$87.07 conversion price), and capped calls have an initial cap price of ≈$119.33 per share.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced NMPA approval of REDEMPLO (plozasiran) for reducing triglyceride levels in adults with familial chylomicronemia syndrome (FCS) in China on January 7, 2026.
Under an agreement with Sanofi, Sanofi will market REDEMPLO in Greater China and the NMPA approval triggers a $10 million milestone payment to Arrowhead subsidiary Visirna Therapeutics. This is REDEMPLO’s third regulatory approval following approvals by the U.S. FDA and Health Canada. REDEMPLO is a siRNA therapy administered by subcutaneous injection once every three months.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced proposed public offerings of $500 million aggregate principal amount of convertible senior notes due January 15, 2032 and $200 million of common stock, each with 30-day underwriter overallotment options of $75 million and $30 million, respectively.
Notes will be senior unsecured, accrue interest semi‑annually, be convertible in specified circumstances, and may be redeemable for cash on or after January 16, 2029. Arrowhead intends to use proceeds for capped call hedges, general corporate purposes, R&D, clinical trials, commercialization preparation and possible prepayment of credit facility loans.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced interim Phase 1/2a data for RNAi obesity candidates ARO-INHBE and ARO-ALK7 on January 6, 2026.
Key results: ARO-INHBE plus tirzepatide produced mean weight loss of -9.4% at week 16 versus -4.8% with tirzepatide alone; combination showed -23.2% visceral fat, -15.4% total fat and -76.7% liver fat reductions (week 12 MRI). ARO-INHBE monotherapy reduced visceral fat -9.9% (single dose, week 16) and -15.6% (two doses, week 24). ARO-ALK7 achieved mean adipose ALK7 mRNA knockdown of -88% (200 mg, week 8) and placebo-adjusted visceral fat -14.1% at week 8.
Both agents were generally well tolerated; one SAE (limb abscess) was reported and assessed unrelated to treatment.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that Health Canada issued a Notice of Compliance authorizing REDEMPLO (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) for whom standard therapies are inadequate.
The approval is based on Phase 3 PALISADE data showing a median triglyceride change of -80% on 25 mg REDEMPLO versus -17% for pooled placebo over 12 months, and a lower numerical incidence of acute pancreatitis; common adverse reactions (≥15%) included hyperglycemia, headache, nausea, and injection site reaction. REDEMPLO is the first Health Canada–approved siRNA for FCS and is dosed by subcutaneous self-injection once every three months.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced participation in two January 2026 events: an Obesity KOL Webinar presenting interim clinical data for ARO-INHBE and ARO-ALK7 on January 6, 2026 at 11:30 a.m. ET, and a corporate presentation at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 at 10:30 a.m. ET.
Presentation materials and webcast links, if available, will be posted on the company’s Events and Presentations page under Investors.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that on December 12, 2025 its board approved inducement equity grants for 78 new employees under NASDAQ Rule 5635(c)(4).
The grants entitle those employees, in aggregate, to receive up to 141,310 restricted stock units. The awards are outside the company’s stockholder-approved equity plans and vest annually over four years.